

## Shelf-Life Extension for EVUSHELD

EVUSHELD (tixagevimab and cilgavimab for injection) has received notification of shelf-life extension by Health Canada for Lot CAAN to **December 31, 2022**.

### Healthcare professionals are advised that:

On July 15, 2022, Health Canada authorized a shelf life update for EVUSHELD (tixagevimab and cilgavimab for injection) for Lot CAAN. The new expiry date is December 31, 2022, when stored at 2 to 8°C. This shelf life update was based on additional stability data reviewed by Health Canada.

The expiration date of EVUSHELD vials must be verified prior to administration (see Products affected section).

Canadian-specific labelling information, including the EVUSHELD Canadian Product Monograph (CPM), can be accessed at [astrazeneca.ca](http://astrazeneca.ca), or by scanning the QR code on the global English-only carton label to visit [www.laab.azcovid-19.com](http://www.laab.azcovid-19.com). This information is also available on the federal government's [covid-vaccine.canada.ca](http://covid-vaccine.canada.ca) website.

For complete details visit: <https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/evusheld-dhcpl-shelf-life-extension-en.pdf>

### Verifying Accuracy of Dispensed Prescriptions and Communicating Effectively

As required by the NAPRA Standards of Practice (see 1.3 and 3.1 at: [https://saskpharm.ca/document/9715/NAPRA\\_Model\\_Standards\\_of\\_Practice\\_Adapted\\_2022.pdf](https://saskpharm.ca/document/9715/NAPRA_Model_Standards_of_Practice_Adapted_2022.pdf)), pharmacy professionals must verify the accuracy of a dispensed prescription and communicate with patients effectively.

As per previous communication from Saskatchewan College of Pharmacy Professionals, pharmacy professionals should consider the following actions when dispensing the impacted lot# of EVUSHELD:

- Blacking out the expiry dates on the product, and applying a label showing the new expiration date;
- Verifying the expiration date prior to dispensing; and
- Reviewing the modifications with the patient to reassure them it is safe to use.

### Who to Call:

If you or your patients have any questions, please call:

- Drug Plan and Extended Benefits Branch at 306-787-3317 (Regina) or 1-800-667-7581.